| Bioactivity | SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research[1]. |
| Invitro | SIRT6-IN-3 (25 μM，48 小时) 诱导 PDAC 细胞周期阻滞和细胞凋亡[1]。SIRT6-IN-3 (25 μM，72 小时) 通过抑制细胞信号通路来抑制胰腺癌细胞的增殖[1]。 0 --> SIRT6-IN-3 相关抗体: Apoptosis Analysis[1] Cell Line: |
| In Vivo | SIRT6-IN-3 (HY-156027；20 mg/kg，腹腔注射；两天一次，连用四周) 在肿瘤小鼠模型中有抗肿瘤作用[1]。SIRT6-IN-3 (HY-156027；20 mg/kg，腹腔注射；两天一次，连用四周) 在与吉西他滨 (比例 2 : 1 ) 联用时增强了吉西他滨的抗肿瘤作用[1]。 Animal Model: |
| Name | SIRT6-IN-3 |
| Formula | C21H30Br3ClN6S |
| Molar Mass | 673.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Song N, et al. Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine. Cell Death Dis. 2023 Aug 4;14(8):499. |